Preclinical strategies to enhance NK cell-mediated tumor elimination include the incorporation of CARs to redirect cytotoxicity, suppression of inhibitory receptors such as NKG2A to improve tumor specificity, and stimulation of NK cell persistence in vivo through autocrine cytokine signaling with IL-2 and IL-15 (22). Here, IL2 is linked to neoplasm.